Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Jefferies Upgrades Merck (MRK) to Hold
October 31, 2017 3:51 AM EDTJefferies upgraded Merck (NYSE: MRK) from Underperform to Hold with a price target of $55.00 (from $54.00).
Analyst Jeffery Holford believes the sharp move lower recently has removed much of the downside he previously suspected would manifest and now moves to the... More
Merck (MRK) Defended at BMO Capital
October 30, 2017 1:13 PM EDTBMO Capital analyst Alex Arfaei came out to defend Merck (NYSE: MRK) which is down 5.9% after the company announced that it has withdrawn its European application for KEYTRUDA® (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell... More
Merck (MRK) PT Lowered to $64 at Bernstein
October 30, 2017 8:09 AM EDTBernstein lowered its price target on Merck (NYSE: MRK) to $64.00 (from $65.00) while maintaining a Outperform rating.
Analyst Tim Anderson defends the name noting he continues to view the IO landscape as a "fluid one" and notes risks to IO forecasts are... More
Merck (MRK) PT Lowered to $69 at Leerink Partners
October 30, 2017 7:49 AM EDTLeerink Partners lowered its price target on Merck (NYSE: MRK) to $69.00 (from $70.00) while maintaining a Market Perform rating following results
Analyst Seamus Fernandez said the majority of the bottom-line beat came from other income and a lower-than-anticipated tax rate.
... MoreWall Street slips as Merck drops, tax talk rattles
October 30, 2017 7:21 AM EDTBy Lewis Krauskopf
(Reuters) - Wall Street pulled back from record-high territory on Monday, weighed down by a drop in Merck shares and a report that U.S. lawmakers are discussing a gradual phase-in of much-anticipated corporate tax cuts.
Market watchers pointed to declines steepening after a Bloomberg report that the House of Representatives was discussing a gradual cut in corporate tax rates over several years.
"A lot of people are looking to that corporate tax cut as a reason for the next leg up in stocks," said Rick Meckler, president of LibertyView Capital Management in Jersey City,... More
SunTrust Robinson Humphrey Downgrades Merck (MRK) to Hold
October 30, 2017 5:26 AM EDTSunTrust Robinson Humphrey downgraded Merck (NYSE: MRK) from Buy to Hold with a price target of $54.00 (from $73.00).
Analyst John Boris adjusts his model to account for Keytruda application withdraw and rising competition for Merck.
For an analyst ratings summary and... More
Morgan Stanley Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:11 AM EDTMorgan Stanley downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $56.00 (from $69.00).
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $58.24 Friday.
... MoreBarclays Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:05 AM EDTBarclays downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $62.00 (from $72.00).
Analyst Geoff Meacham cites limited upside potential for the equity originating from Keytruda which is "by far Meerck's biggest value driver." The analyst notes headwinds to the... More
Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC
October 27, 2017 4:18 PM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has withdrawn its European application for KEYTRUDA® (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).
... More
Wall St. powered higher by tech, Amazon results
October 27, 2017 7:38 AM EDTBy Chuck Mikolajczak
NEW YORK (Reuters) - Wall Street climbed on Friday as a surge in the tech sector and a rally in Amazon shares helped push the Nasdaq to its best day in nearly a year.
The S&P technology index led the way higher, up 2.91 percent. The index notched its best day since March 1, 2016, and is up nearly 35 percent on the year versus the 15 percent gain in the S&P 500.
Google-parent Alphabet (NASDAQ: GOOGL) gained 4.26 percent as its revenue got a boost from advertising sales.
Microsoft (NASDAQ:... More
Merck (MRK) Tops Q3 EPS by 8c, Lifts FY EPS Gudiance
October 27, 2017 6:46 AM EDT(Updated - October 27, 2017 6:49 AM EDT)
Merck (NYSE: MRK) reported Q3 EPS of $1.11, $0.08 better than the analyst estimate of $1.03. Revenue for the quarter came in at $10.3 billion versus the consensus estimate of $10.55 billion.
Financial... More
